key: cord-0683220-g3vq0u7z authors: Katagiri, Daisuke; Ishikane, Masahiro; Ogawa, Tatsunori; Kinoshita, Noriko; Katano, Harutaka; Suzuki, Tadaki; Fukaya, Takashi; Hinoshita, Fumihiko; Ohmagari, Norio title: Continuous Renal Replacement Therapy for a Patient with Severe COVID-19 date: 2020-06-11 journal: Blood Purif DOI: 10.1159/000508062 sha: 0b6f43ff10ff63de87d94272885b02039c850efc doc_id: 683220 cord_uid: g3vq0u7z The outbreak of coronavirus disease 2019 (COVID-19) is a global health threat. It is a respiratory disease, and acute kidney injury (AKI) is rare; however, if a patient develops severe AKI, renal replacement therapy (RRT) should be considered. Recently, we had a critically ill COVID-19 patient who developed severe AKI and needed continuous RRT (CRRT). To avoid the potential risk of infection from CRRT effluents, we measured severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genetic material in the effluents by qRT-PCR, and low copy numbers of the viral genome were detected. Due to unstable hemodynamic status in critically ill patients, CRRT should be the first choice for severe AKI in COVID-19 patients. We suggest prevention of clinical infection and control during administration of RRT in the acute phase of COVID-19 patients with AKI or multiple organ failure. Acute kidney injury (AKI) is a life-threatening disorder, although the rate of AKI in COVID-19 is relatively rare. According to reports from Wuhan, China, among 138 hospitalized patients with COVID-19, only 5 (3.6%) patients developed AKI and 2 (1.5%) patients required continuous renal replacement therapy (CRRT) [1] . There are no data about managing CRRT, including prevention of secondary infection and control (IPC) in COVID-19 patients. Here, we report a case of a patient with severe COVID-19 who required CRRT. A septuagenarian male suffering from COVID-19 was referred to our hospital. On day 3, tracheal intubation was performed and mechanical ventilation was initiated. His sCre gradually decreased from 1.34 mg/dL (day 1) to 1.06 mg/dL (day 6). As the urine output gradually decreased, sCre increased from day 7 and reached 3.46 mg/dL on day 9, when CRRT was initiated. Nafamostat mesylate was used for anticoagulation. Cytokine-absorbing polymethyl methacrylate membrane [2, 3] was used as a hemofilter. During the management of CRRT, there is a risk of the presence of the virus in the CRRT effluent [4] . To evaluate this possibility, we measured SARS-CoV-2 genetic material in the CRRT effluent by qRT-PCR Katagiri et al. [5] . A very weak but positive RT-PCR result was detected in 3 of 5 specimens (Table 1) . We disposed the CRRT effluent in a container using fluid coagulant agent, closed the lid, and treated it as hazardous waste. Though the patient developed anuria, X-ray showed better aeration with continuous removal of water by CRRT, and the patient was extubated on day 22. According to a recent report from Wuhan, China, among 52 critically ill adult patients with COVID-19 pneumonia who were admitted to the ICU, 12 (23%) patients developed AKI and 9 (17%) required renal replacement therapy (RRT) [6] . Higher morbidity has been reported among the elderly and in those with coexisting disease conditions [7] . With the increasing number of COVID-19 patients, the need for RRT is likely to increase. To prevent the spread of infection, all staff who managed CRRT wore personal protective equipment comprising standard, contact, and droplet precautions; gloves; N95 mask; gown; cap; and face shield. Although the recommendation by the WHO for the use of personal protective equipment for COVID-19 did not include CRRT [8] , we considered the risk of aerosol generation during CRRT. The pore size of a hemofilter is 7-10 nm [9] and the size of 2019-nCoV is about 100 nm [10] , which suggests that the permeability of 2019-nCoV into CRRT effluent is significantly low. Therefore, these results need to be evaluated in further studies. Additional examination including virus isolation should be considered to evaluate whether the effluent from CRRT is clinically infectious. To the best of our knowledge, this is the first report describing the management of CRRT including IPC among COVID-19 patients. From our experience, we suggest clinical practice and IPC for delivering RRT in the acute phase in COVID-19 patients who develop AKI (Table 2) . CRRT effluent samples were taken on day 11 (1, 3, and 6 h after CRRT start) and on day 14 (1 and 3 h after CRRT start). Data are presented as virus copies per 1 µL (Ct). Lower cycle threshold (Ct) values indicate higher viral loads. RT-PCR was performed using Quantitect probe one-step RT-PCR kit (Qiagen, MD, USA) with the following probe and primer sets; WuhanCoV-spk2-f 5′-TTTCCTC-GTGAAGGTGTCTTTGT-3′, WuhanCoV-spk2-r 5′-TGTGGTTCATAAAAATTCCTTTGTG-3′, and WuhanCoV-spk2-hex-p 5′-HEX-TCAAATG-GCACACACTGGTTTGT-BHQ1 targeting spike gene (24,843-24,916 in GenBank accession MN908947); Wu-hanCoV-N1f 5′-GGCCGCAAATTGCACAAT-3′, WuhanCoV-N1r 5′-CCAATGCGCGACATTCC-3′, and WuhanCoV-N1pr-fam 5′-FAM-CCCCCAGCGCTTCAGCGTTCT-TAMRA-3′ targeting nucleoprotein gene (29, 251 in MN908947). SOFA, sequential organ failure assessment; CRRT, continuous renal replacement therapy; AKI, acute kidney injury; UD, undetected. Blood Purif DOI: 10.1159/000508062 This research was conducted ethically in accordance with the World Medical Association Declaration of Helsinki. The study protocol was approved by the Institutional Review Board (approval No. NCGM-G-003472-02). Written informed consent for publication was obtained from the patient. The authors have no conflicts of interest to declare. This work was supported by grants from the Japan Agency for Medical Research and Development, AMED (JP19fk0108104). Wipe outside of the container with alcohol, then treated as hazardous waste, and dispose ICU, intensive care unit; CRRT, continuous renal replacement therapy; PPE, personal protective equipment; AKI, acute kidney injury; PMMA, polymethyl methacrylate; AS69ST, polyethylenimine-coated polyacrylonitrile. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan Cytokine removal in extracorporeal blood purification: an in vitro study Continuous hemodiafiltration with PMMA hemofilter in the treatment of patients with septic shock Successful delivery of RRT in Ebola virus disease National Institution of Infectious Disease in Japan. Manual for the detection of pathogen 2019-nCoV Ver.2.6 Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study Covid-19: navigating the uncharted Rational use of personal protective equipment for coronavirus disease 2019 (COVID-19), Interim guidance Continuous hemodialfiltration using PMMA membrane: clinical efficacy and its mechanisms Enhanced isolation of the novel 2019 coronavirus by TMPRSS2-expressing cells We thank all the clinical staff at the National Center for Global Health and Medicine (NCGM) for their dedicated clinical practice and patient care.